{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
methylene blue
to a specific field?
Status:
Designated
Source:
FDA ORPHAN DRUG:887822
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Designated
Source:
EU-Orphan Drug:EU/3/14/1408
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Designated
Source:
EU-Orphan Drug:EU/3/08/568
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Designated
Source:
EU-Orphan Drug:EU/3/17/1935
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
U0126 is a highly selective inhibitor of both MEK1 and MEK2, a type of MAPK/ERK kinase. The inhibitory effects of U0126 on MEK and ERK activation have been confirmed repeatedly, and treatments with U0126 have been shown to inhibit proliferation and migration of cancer cells in vivo and in vitro. U0126 has been widely used as an inhibitor for the Ras/Raf/MEK/ERK signaling pathway. U0126 treatments lead to cancer cell death, which agrees with the well-known role of the Ras/Raf/MEK/ERK pathway in supporting cell survival. U0126 enhances apoptosis in human breast cancer MCF-7 cells, acute myeloid leukemia, and PC12 cells.
![Structure of 1,3-Diethyl 2-[(2,5-dimethoxyphenyl)methylene]propanedioate](/img/6f536319-86ea-48c2-b04e-ba1edae612bc.svg?size=200&context=aymplrddqm)
![Structure of (4,4'-Bis(4-cyanophenoxy)-[1,1'-biphenyl]-2,2'-diyl)bis(methylene)diacetate](/img/f1dc7356-5e07-4b3a-b1e3-0d806d7c4dc6.svg?size=200&context=aymplrddqm)
